Merck & Co.
About Merck & Co.
About our Company
We aspire to be the premier research-intensive biopharmaceutical company in the world. Innovation and scientific excellence are at the core of what we do in pursuit of our mission to save and improve lives. Together, we invent for a more hopeful future.
Who we are
Our company, Merck (known as MSD outside of the U.S. and Canada), is a global health care leader with a diversified portfolio of prescription medicines, vaccines, and animal health products. For more than 125 years we have been inventing for life. Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases like HIV and Ebola, and emerging animal diseases.
We hire the most brilliant minds because inventing for life depends on our work. Our dedicated employees come from an array of backgrounds and do many different things --from research and development and business technology to marketing and pharmaceutical sales. Yet each of us knows our work matters.
At Merck, you'll find rewarding opportunities, diverse experiences, and an unwavering commitment to ethics and integrity. You'll collaborate with talented colleagues who share your sense of purpose. Our company will empower you to innovate, explore, and develop your full potential in our possibility-rich environment. Join our team and help us invent, impact, and inspire every day.
3447 articles with Merck & Co.
-
Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
6/9/2021
U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration
-
The $7 billion transaction by Datavant with Ciox Health will be the nation's largest "neutral and secure health data ecosystem."
-
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
6/7/2021
Results From New Analysis Evaluating Health-Related Quality of Life (HRQoL) Based on Patient-Reported Outcomes Using Three HRQoL Scales
-
An ugly symbol of racism appears to have reared its head at a Merck facility in North Carolina. The pharma giant is investigating reports of a noose found hanging at a construction project on the 262-acre facility.
-
Shares of Fate climbed nearly 4% in premarket trading after it announced positive interim data from a Phase I study of FT516 for patients with relapsed / refractory B-cell lymphoma.
-
Merck Announces Completion of Organon & Co. Spinoff
6/3/2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable growth and value,” said Rob Davis, president, M
-
LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial
6/3/2021
First Medicine Specifically Targeting BRCA Mutations to Demonstrate Statistically Significant Improvement in Invasive Disease-Free Survival in Adjuvant Setting Following Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
-
Organon’s focus will center on reproductive health, health conditions, and issues unique to women and diseases that disproportionately impact women.
-
Researchers at multiple companies and institutes are doggedly pursuing clinical programs so the virus can become little more than a hindrance in the future.
-
The new vaccination, dubbed VAXELIS, is indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.
-
Sanofi and Merck's first and only six-in-one pediatric combination vaccine now available in the United States
6/1/2021
This combination vaccine may simplify execution and reduce shots needed to complete CDC's recommended child and adolescent immunization schedule
-
Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States
6/1/2021
This Combination Vaccine May Simplify Execution and Reduce Shots Needed to Complete CDC’s Recommended Child and Adolescent Immunization Schedule
-
The company, which isn’t expected to enter the clinic until possibly in 2022, is working to make cell therapies work in solid tumors.
-
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
-
Xilio Therapeutics Announces Clinical Trial Collaboration With Merck on Anti-CTLA-4 Monoclonal Antibody Program
5/25/2021
Xilio to evaluate XTX101, a tumor selective anti-CTLA-4 monoclonal antibody, in combination with KEYTRUDA® (pembrolizumab) as a treatment for patients with solid tumors
-
The clinical trial, which will be conducted by Xilio, will assess XTX101's safety and efficacy as a monotherapy, as well as in combination with Keytruda, in solid tumors.
-
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
5/24/2021
Recommendation Based on Significant Survival Benefit Demonstrated With KEYTRUDA Plus Chemotherapy Versus Chemotherapy in Phase 3 KEYNOTE-590 Trial
-
NGM Bio's aldafermin failed to hit its primary endpoint in its Phase IIB trial because of that, the company decides to shift resources to other programs.
-
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
-
Maria Fardis, who has been with the company since 2016, stepped down as CEO following FDA's delay on its Biologics License Application.